Bladder CIS Extent Predicts Post-BCG Disease Progression
Treatment with bacillus Calmette-Guérin (BCG) is effective for carcinoma in situ (CIS) of the bladder, according to Japanese researchers.
Diagnosis & Disease Information
Technique Clears Obstructed Ureters
WASHINGTON D.C.—The placement of transileal retrograde nephrostomy catheters (rPCN) is a safe and effective treatment for post-surgical ureteral obstruction following non-continent urinary diversion procedures, according to new data presented here at the 33rd Annual Scientific Meeting of the Society of Interventional Radiology (SIR).
High CRP Worsens Prognosis
Elevated C-reactive protein (CRP) levels before chemoradiotherapy for muscle-invasive bladder cancer is associated with a poor prognosis, according to researchers at Tokyo Medical and Dental University in Japan.
Manufacturing Issue Delays Restart of CIS Drug
Indevus Pharmaceuticals, Inc., of Lexington, Mass., has received a non-approvable letter from the FDA for Valstar (valrubicin solution), the only approved product for therapy of bacillus Calmette-Guérin-refractory carcinoma in situ of the urinary bladder.
TCC in Transplant Patients
Transitional cell carcinoma (TCC) is the predominant malignancy to develop in Chinese renal transplant recipients, according to researchers at the Capital University of Medical Sciences in Beijing.
Robotic Cystectomies Have Advantages
Robotic radical cystectomy (RC) may offer advantages over open surgery without compromising pathologic measures of early oncologic efficacy, researchers suggest.
One Third of Standard BCG Dose May Be Sufficient
One third of the standard dose of bacillus Calmette-Guérin (BCG) could be recommended as adjuvant treatment for intermediate-risk superficial bladder tumors, Spanish researchers say.
Man Wins $1.6 Million in Missed Bladder Cancer Case
A terminally ill Illinois man has won a $1.6 million verdict against the general practitioner who failed to diagnose bladder cancer.
Gemcitabine Prevents TCC Relapse
CHICAGO—Intravesical gemcitabine is an effective and well tolerated adjuvant local chemotherapy in patients with superficial bladder cancer, according to researchers in Algeria.
Bladder Cancer Sex Differences
Twice as many men as women are treated for bladder cancer, according to a study.
- Loading...
Loading...
Loading... 
Loading...